The anti-infective drugs market consists of sales of anti-infective drugs and related services by entities (organizations, sole traders and partnerships) that produce anti-infective drugs to treat microbial infections. This industry includes establishments that produce antibiotics to treat bacterial infections, anti-viral drugs to treat viral infections, anti-fungal drugs to treat fungal infections, anti- helminthic drugs to kill internal parasites and antiprotozoal agents.
The global anti-infective drugs market is expected to grow from $106.5 billion in 2019 to $139.3 billion in 2020 at a compound annual growth rate (CAGR) of 30.8%. The significant growth is mainly due to the COVID-19 outbreak and the huge demand for anti-viral and antibiotic drugs. Although other anti-infective drugs like antifungals have seen a dip in sales, the enormous demand for antiviral drugs and antibiotic drugs such as Azithromycin, Chloroquine, Acyclovir, and Ribavirin among others have contributed to the overall market growth of anti-infective drugs. The market is then expected to recover and grow at a CAGR of 6% from 2021 and reach $159.6 billion in 2023. North America was the largest region in the global anti-infective drugs market, accounting for 50% of the market in 2019. Asia Pacific was the second largest region accounting for 20% of the global anti-infective drugs market. Africa was the smallest region in the global anti-infective drugs market. Companies in this market are active with multiple strategic collaborations and agreements. Top companies in the anti-infective drug market are strategically partnering and collaborating with other companies to broaden their products and services. For instance, in May 2015, Janssen Pharmaceuticals Inc., subsidiary of Johnson & Johnson has entered into an exclusive worldwide license and collaboration arrangement with Achillion Pharmaceuticals Inc. to develop and commercialize one or more of Achillion`s lead hepatitis C virus (HCV) assets which include ACH-3102, ACH-3422 and sovaprevir . Also in December 2017, Evotec AG was in a strategic alliance with Forge Therapeutics Inc. to advance its novel Gram-negative antibiotic programme targeting LpxC for the treatment of bacterial infections. Chimerix and ContraVir Pharmaceuticals also entered into a strategic collaboration for antiviral drug candidate CMX157
The major players in the global anti-infective drugs market are Gilead, Merck & Co, GlaxosmithKline, Bristol-Myers Squibb Company, Johnson & Johnson
The countries covered in the global anti-infective drugs market report are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela, Vietnam
The global anti-infective drugs market is segmented:
1) By Type: Antibiotics, Antivirals, Antifungals, Others (Anthelminthic, Antiprotozoal)
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Others
3) By Route Of Administration: Oral, Parenteral, Others
4) By Drug Classification: Branded Drugs, Generic Drugs
5) By Mode Of Purchase: Prescription-Based Drugs, Over-The-Counter Drugs